See a Demo

Category: Blog

TrialAssure cubes divider
TrialAssure In support of an ongoing effort to increase transparency, Health Canada intends to implement five proposals related to prescription drugs and biologics by October 1, 2018. The proposals come from a division within Health Canada—the Health Products and Food Branch (HPFB)—as part of two 2015 transparency initiatives for drugs, biologics and medical devices.

This week in transparency news: March 30 – April 5, 2019

by Staff Writer | April 2019

Posted in Blog
Read More
Should people share their DNA for drug development purposes? – USA Today Many people don’t realize that sharing a DNA sample with Ancestry.com, 23andMe and others can result in their data being shared. However, this week, the companies pledged that they would disclose when data is shared with corporations or the government. With a $300 million investment by GSK in 23andMe, they state that approximately 80 percent of customers have agreed to share their DNA data. This data is being de-identified before it is shared.

This week in transparency news: March 23 – March 29, 2019

by Staff Writer | March 2019

Posted in Blog
Read More
lay summaries pls plain language summary trialassure

This week in transparency news: March 16 – March 22, 2019

by Staff Writer | March 2019

Posted in Blog
Read More

This week in transparency news: March 2 – March 15, 2019

by Staff Writer | March 2019

Posted in Blog
Read More
trialassure clinical trial transparency news

This week in transparency news: February 23 – March 1, 2019

by Staff Writer | March 2019

Posted in Blog
Read More

This week in transparency news: February 16 – February 22, 2019

by Staff Writer | February 2019

Posted in Blog
Read More
Should people share their DNA for drug development purposes? – USA Today Many people don’t realize that sharing a DNA sample with Ancestry.com, 23andMe and others can result in their data being shared. However, this week, the companies pledged that they would disclose when data is shared with corporations or the government. With a $300 million investment by GSK in 23andMe, they state that approximately 80 percent of customers have agreed to share their DNA data. This data is being de-identified before it is shared.

This week in transparency news: February 9 – February 15, 2019

by Staff Writer | February 2019

Posted in Blog
Read More
The U.S. Senate had voted in favor of an opioid bill that expands Open Payments to include payments made to Nurse Practitioners, Physician Assistants, Nurse Midwifes, Nurse Anesthetists, and Clinical Nurse Specialists, in addition to current physician reporting requirements. This will go into effect beginning January 1, 2022. Inconsistent Clinical Trial Disclosure and Lack of Compliance Across Big Pharma

This week in transparency news: February 2 – February 8, 2019

by Staff Writer | February 2019

Posted in Blog
Read More

This week in transparency news: January 26 – February 1, 2019

by Staff Writer | February 2019

Posted in Blog
Read More

This week in transparency news: January 19-25, 2019

by Staff Writer | January 2019

Posted in Blog
Read More
Get in Touch

Looking to streamline your clinical trial disclosure and transparency efforts?

TrialAssure is ready to help your organization embark on a Transparency Transformation!

To learn more about the TrialAssure Transparency Suite, specific products, or our company, contact us below.

Yes, please send me more information about TrialAssure.

  • *